Akorn (AKRX): Notes From Management Meetings - Jefferies
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Akorn (NASDAQ: AKRX) after hosting the company for two days of investor meetings. A focal point was market dynamics for AKRX’s largest product ephedrine ($200M+). This remains a very fluid situation with many factors at play.
Other key topics included AKRX’s 86 ANDA pipeline & M&A. Post these meetings, the analyst expects near term volatility as the ephedrine story plays out but the analyst likes the risk-reward profile at current levels given likely robust new product flow and potential acquisitions.
No change to the price target of $35.00
Shares of Akorn closed at $26.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex Pharma (VRTX): Recent Volatility Is a Buying Opportunity - Jefferies
- Lionsgate (LGF): Starz Deal Accretive To A Cheap Stock - Brean Capital
- Starbucks Coffee (SBUX): Investor Day Offers Little New - Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, Management Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!